Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Exclusion Criteria

• •ECOG Performance status of 0 or 1
• •Available tumor sample for testing
• •Acceptable blood work
• •Primitive peritoneal, pericardial and tunica vaginalis testis mesotheliomas
• •Prior chemotherapy for pleural mesothelioma
• •Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 oranti-CTLA-4 antibody
• •History of other malignancy unless the subject has been disease-free for at least 3 years
• •Active, untreated central nervous system (CNS) metastasis